Healx
AI drug discovery | Rare disease treatment
Cambridge, United Kingdom · Founded 2014 · $113.0M raised
- Headquarters
- Cambridge
- Employees
- 51–200
- Founded
- 2014
- Business Model
- B2B
- Website
- healx.ai
- Total Funding
- $113.0M
- Last Round
- $47.0M Series CAug 2024
- Rounds
- 3
About
Healx is an AI-powered, patient-inspired clinical-stage biotech company that accelerates the discovery and development of treatments for rare diseases. Using its next-generation AI platform, Healx identifies novel drug-disease connections from millions of data points and advances candidates through a pipeline targeting rare neurology, rare oncology, and related conditions. The company has raised over $100M and is headquartered in Cambridge, UK.
Summary
Healx is an Artificial Intelligence company based in Cambridge, United Kingdom, founded in 2014. It has raised $113.0M in total across 3 rounds, most recently a $47.0M Series C round in Aug 2024. Investors include Balderton Capital, Atomico and R42 Group.
Tech & App Stack
6 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2024
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Neuralink is building a brain-computer interface for medical needs and greater human potential.
OpenAI is an AI research and deployment company dedicated to ensuring that general-purpose artifi...
Anthropic is an AI research company that builds reliable, interpretable, and steerable AI systems.